Compare Cassava Sciences Inc (FLNA) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $7.00B). The key difference: Invesco S&P 500 Low Volatility ETF is far larger — about 177.7× Cassava Sciences Inc's market cap, and Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| FLNA | SPLV | |
|---|---|---|
Market Cap | $39.40M | $7.00B |
Volume | 759,018 | 1,622,563 |
Sector | Health | — |
52-Week High | $4.64 | $77.97 |
52-Week Low | $0.68 | $70.30 |
Typical Hold Time | 37 Days | 123 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
SPLV trades at $71.22, down 0.71% with a bearish technical signal from moving averages. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 per share were distributed in July and September 2026, while technical indicators show mixed signals with neutral RSI readings but strong bearish ADX momentum.
The outlook remains challenged by sector headwinds and unappealing growth-adjusted valuation at 19.5x P/E. Key risks include continued underperformance relative to broader market and sensitivity to interest rate movements. Opportunities exist for investors seeking low-volatility exposure during market uncertainty, though near-term catalysts appear limited.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
